Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00493987 · ClinicalTrials.gov registry record · Phase 4
The Role of 5-alpha Reductase in Mediating Testosterone Actions
A Phase 4 study of Healthy, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Completed
- Registry status
- Phase 4
- Development phase
- 184
- Enrollment target
- 1
- Study location
NCT00493987: Completed Phase 4 study of Healthy, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
NCT00493987 is a Phase 4 study of Healthy that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 184 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00493987, a Phase 4 study of Healthy, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 184 participants
- Enrollment target
- 1
- Study location
Study Summary
In normal men, the male hormone testosterone affects a number of things in the body including muscle function and sexual function. An enzyme in the body called 5-alpha reductase converts testosterone into another form called dihydrotestosterone (DHT) which has slightly different effects. The purpose of this study is to find out how different amounts of the two different forms of testosterone affect muscle function and sexual function in healthy young men like you. This will be done by giving the men participating in the study different combinations of hormone-related medication for 20 weeks and making measurements before, during and after the medications to look for changes in lean body tissue, muscle size, muscle strength and leg power, as well as sexual function and sexual activity in all participants.
Conditions Studied
Interventions
- DRUG Testosterone Enanthate
- DRUG Dutasteride
Study Locations (1)
Massachusetts
- Boston University Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2002-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
What the finished NCT00493987 record still lists
NCT00493987 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Testosterone Enanthate is the first listed.
NCT00493987 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00493987 about?
NCT00493987 is a clinical study titled "The Role of 5-alpha Reductase in Mediating Testosterone Actions". In normal men, the male hormone testosterone affects a number of things in the body including muscle function and sexual function. An enzyme in the body called 5-alpha reductase converts testosterone into another form called dihydrotestosterone (DHT) which has slightly different effects. The purpose...
What is the current status of trial NCT00493987?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 184 participants. The study started on 2002-11. Estimated completion is 2010-03.
What conditions does trial NCT00493987 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00493987?
The interventions under investigation include: Testosterone Enanthate (DRUG), Dutasteride (DRUG).
Who is sponsoring clinical trial NCT00493987?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00493987 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00493987's enrollment target sits among peer trials
184 132nd of 1090 higher than 959 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
-
Pharmacokinetics of Transdermal Metronidazole
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia